Accès ouvert

Prevalence and Risk Factors of Rifampicin Resistant Mycobacterium Tuberculosis among Human Immune Virus Sero-Positive Patients in South Western Uganda

Article scientifique 2023 Anglais

Résumé

Abstract Background Tuberculosis is treated using rifampicin and isoniazid as the first line drugs, with rifampicin playing a pivotal role in the effective treatment of tuberculosis. However, resistance to rifampicin is common and used as a valuable surrogate marker for multi-drug resistant tuberculosis (MDR-TB). Furthermore, HIV co-infection complicates the management of PTB. Methods Across sectional study was conducted in South Western Uganda between December 2014 and May 2015. A total of 859 smear positive and smear negative HIV-positive individuals who were presumptive for TB, newly diagnosed and previously treated TB patients, aged ≥ 18years were enrolled. A standardized questionnaire was administered to patients who consented to collect their socio-demographic characteristics and risk factors for TB. Sputum samples were obtained from the participants and GeneXpert MTB/RIF assay performed. Data was analyzed for proportions and factors associated with rifampicin resistant TB (RR-TB) in a multivariate analysis. Results A total of 510 (59.4%) were male, 238 (27.8%) were new cases and 159 (18.5%) were M. tuberculosis positive. The prevalence of RR-TB was 09 (5.7%). Male HIV-positive individuals had a higher risk of contracting TB than females (P = 0.001). Rifampicin resistant M. tuberculosis was 06 (1.2%) among male and03 (0.9%) among female TB patients. Having rifampicin resistant M. tuberculosis was significantly associated, OR (95%CI: P value) with TB history 4.99 (95% CI; P = 0.001) and smoking tobacco 2.05 (95% CI: P = 0.001). Conclusion There is a considerable high prevalence of PTB in South western Uganda despite the low magnitude of RR-TB among HIV positive individuals. Risk factors such as history of TB, and smoking should be included in the preventive measures for better outcomes. Continuous screening of HIV-positive individuals for TB and RR-TB is highly recommended.

Citer ce document

Nakigozi, H., Mukama, P., Tumwine, G., Nanteza, A., Kato, C., Owinyi, D., Othieno, E., Nabadda, S., Ssengooba, W. (2023). Prevalence and Risk Factors of Rifampicin Resistant Mycobacterium Tuberculosis among Human Immune Virus Sero-Positive Patients in South Western Uganda. https://doi.org/10.21203/rs.3.rs-3486350/v1

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Voir l'article sur le site de la revue

Auteur(s)

Harriet Nakigozi Paul Mukama Gabriel Tumwine Ann Nanteza Charles Drago Kato David Okello Owinyi Emmanuel Othieno Susan Nabadda Willy Ssengooba

Statistiques

Consultations : 1

Téléchargements : 0